Efficacy of methylprednisolone on pain, fatigue, and appetite loss in patients with advanced cancer using opioids: a randomized, placebo-controlled, double-blind trial
- PMID: 25002731
- DOI: 10.1200/JCO.2013.54.3926
Efficacy of methylprednisolone on pain, fatigue, and appetite loss in patients with advanced cancer using opioids: a randomized, placebo-controlled, double-blind trial
Abstract
Purpose: Corticosteroids are frequently used in cancer pain management despite limited evidence. This study compares the analgesic efficacy of corticosteroid therapy with placebo.
Patients and methods: Adult patients with cancer receiving opioids with average pain intensity ≥ 4 (numeric rating scale [NRS], 0 to 10) in the last 24 hours were eligible. Patients were randomly assigned to methylprednisolone (MP) 16 mg twice daily or placebo (PL) for 7 days. Primary outcome was average pain intensity measured at day 7 (NRS, 0 to 10); secondary outcomes were analgesic consumption (oral morphine equivalents), fatigue and appetite loss (European Organisation for Research and Treatment of Cancer-Quality of Life Questionnaire C30, 0 to 100), and patient satisfaction (NRS, 0 to 10).
Results: A total of 592 patients were screened; 50 were randomly assigned, and 47 were analyzed. Baseline opioid level was 269.9 mg in the MP arm and 160.4 mg in the PL arm. At day-7 evaluation, there was no difference between the groups in pain intensity (MP, 3.60 v PL, 3.68; P = .88) or relative analgesic consumption (MP, 1.19 v PL, 1.20; P = .95). Clinically and statistically significant improvements were found in fatigue (-17 v 3 points; P .003), appetite loss (-24 v 2 points; P = .003), and patient satisfaction (5.4 v 2.0 points; P = .001) in favor of the MP compared with the PL group, respectively. There were no differences in adverse effects between the groups.
Conclusion: MP 32 mg daily did not provide additional analgesia in patients with cancer receiving opioids, but it improved fatigue, appetite loss, and patient satisfaction. Clinical benefit beyond a short-term effect must be examined in a future study.
© 2014 by American Society of Clinical Oncology.
Comment in
-
Are corticosteroids effective in all patients with cancer-related pain?J Clin Oncol. 2014 Oct 10;32(29):3210-1. doi: 10.1200/JCO.2014.56.7701. Epub 2014 Sep 15. J Clin Oncol. 2014. PMID: 25225427 No abstract available.
-
Reply to a. Molfino et Al.J Clin Oncol. 2015 May 1;33(13):1513. doi: 10.1200/JCO.2014.60.6475. Epub 2015 Mar 9. J Clin Oncol. 2015. PMID: 25753433 No abstract available.
-
Anorexia assessment in patients with cancer: a crucial issue to improve the outcome.J Clin Oncol. 2015 May 1;33(13):1513. doi: 10.1200/JCO.2014.59.9548. Epub 2015 Mar 9. J Clin Oncol. 2015. PMID: 25753439 No abstract available.
Similar articles
-
Efficacy of corticosteroids for cancer-related fatigue: A pilot randomized placebo-controlled trial of advanced cancer patients.Palliat Support Care. 2015 Oct;13(5):1301-8. doi: 10.1017/S1478951514001254. Epub 2014 Nov 5. Palliat Support Care. 2015. PMID: 25370595 Clinical Trial.
-
Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group.J Clin Oncol. 2006 Jul 20;24(21):3394-400. doi: 10.1200/JCO.2005.05.1847. J Clin Oncol. 2006. PMID: 16849753 Clinical Trial.
-
Lack of benefit from paracetamol (acetaminophen) for palliative cancer patients requiring high-dose strong opioids: a randomized, double-blind, placebo-controlled, crossover trial.J Pain Symptom Manage. 2010 Mar;39(3):548-54. doi: 10.1016/j.jpainsymman.2009.07.008. Epub 2010 Jan 18. J Pain Symptom Manage. 2010. PMID: 20083373 Clinical Trial.
-
Placebo effects in oncology.J Natl Cancer Inst. 2003 Jan 1;95(1):19-29. doi: 10.1093/jnci/95.1.19. J Natl Cancer Inst. 2003. PMID: 12509397 Review.
-
A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia.J Palliat Care. 1994 Spring;10(1):14-8. J Palliat Care. 1994. PMID: 8035251 Review.
Cited by
-
The Challenges of Managing Bone Pain in Cancer.Ulster Med J. 2020 Jan;89(1):7-10. Epub 2020 Feb 18. Ulster Med J. 2020. PMID: 32218619 Free PMC article. No abstract available.
-
Dexamethasone for 12 weeks for reducing fatigue in patients receiving palliative chemotherapy: A Phase 3, Placebo-Controlled, Randomized Controlled Trial.Support Care Cancer. 2025 Jul 31;33(8):730. doi: 10.1007/s00520-025-09807-w. Support Care Cancer. 2025. PMID: 40739403 Clinical Trial.
-
Fatigue in Cancer Patients in Palliative Care-A Review on Pharmacological Interventions.Cancers (Basel). 2021 Feb 26;13(5):985. doi: 10.3390/cancers13050985. Cancers (Basel). 2021. PMID: 33652866 Free PMC article. Review.
-
Effect of Systemic Corticosteroid Therapy on the Efficacy and Safety of Nivolumab in the Treatment of Non-Small-Cell Lung Cancer.Cancer Control. 2021 Jan-Dec;28:1073274820985790. doi: 10.1177/1073274820985790. Cancer Control. 2021. PMID: 33733906 Free PMC article.
-
Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance.Nat Commun. 2021 Dec 6;12(1):7041. doi: 10.1038/s41467-021-27349-7. Nat Commun. 2021. PMID: 34873175 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical